Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole

A. Espinel-Ingroff, A. Fothergill, M. Ghannoum, E. Manavathu, L. Ostrosky-Zeichner, M. Pfaller, M. Rinaldi, W. Schell, T. Walsh

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Although standard conditions are available for testing the susceptibilities of filamentous fungi to antifungal agents by the Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) broth microdilution assay, quality control (QC) MIC limits have not been established for any mold-agent combination. This multicenter (eight-center) study documented the reproducibility of tests for one isolate of Paecilomyces variotti ATCC MYA-3630 and 11 other mold isolates (three isolates of Aspergillus fumigatus; two isolates of A. terreus; one isolate each of A. flavus, A. nidulans, Fusarium moniliforme, and F. solani; and two isolates of Scedosporium apiospermum) by the CLSI reference broth microdilution method (M38-A document). Control limits (amphotericin B, 1 to 4 μg/ml; itraconazole, 0.06 to 0.5 μg/ml; posaconazole, 0.03 to 0.25 μg/ml; voriconazole, 0.015 to 0.12 μg/ml) for the selected QC P. variotii ATCC MYA-3630 were established by the analysis of replicate MIC results. Reference isolates and corresponding MIC ranges were also established for 6 of the 12 molds evaluated. MIC limits were not proposed for the other five molds tested due to low testing reproducibility for these isolates.

Original languageEnglish (US)
Pages (from-to)5243-5246
Number of pages4
JournalJournal of clinical microbiology
Volume43
Issue number10
DOIs
StatePublished - Oct 1 2005

Fingerprint

Itraconazole
Amphotericin B
Quality Control
Fungi
Guidelines
Scedosporium
Paecilomyces
Aspergillus fumigatus
Antifungal Agents
Fusarium
posaconazole
Voriconazole

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. / Espinel-Ingroff, A.; Fothergill, A.; Ghannoum, M.; Manavathu, E.; Ostrosky-Zeichner, L.; Pfaller, M.; Rinaldi, M.; Schell, W.; Walsh, T.

In: Journal of clinical microbiology, Vol. 43, No. 10, 01.10.2005, p. 5243-5246.

Research output: Contribution to journalArticle

Espinel-Ingroff, A, Fothergill, A, Ghannoum, M, Manavathu, E, Ostrosky-Zeichner, L, Pfaller, M, Rinaldi, M, Schell, W & Walsh, T 2005, 'Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole', Journal of clinical microbiology, vol. 43, no. 10, pp. 5243-5246. https://doi.org/10.1128/JCM.43.10.5243-5246.2005
Espinel-Ingroff, A. ; Fothergill, A. ; Ghannoum, M. ; Manavathu, E. ; Ostrosky-Zeichner, L. ; Pfaller, M. ; Rinaldi, M. ; Schell, W. ; Walsh, T. / Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. In: Journal of clinical microbiology. 2005 ; Vol. 43, No. 10. pp. 5243-5246.
@article{f4cc35cf5e974f2ca5ff2894a839a603,
title = "Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole",
abstract = "Although standard conditions are available for testing the susceptibilities of filamentous fungi to antifungal agents by the Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) broth microdilution assay, quality control (QC) MIC limits have not been established for any mold-agent combination. This multicenter (eight-center) study documented the reproducibility of tests for one isolate of Paecilomyces variotti ATCC MYA-3630 and 11 other mold isolates (three isolates of Aspergillus fumigatus; two isolates of A. terreus; one isolate each of A. flavus, A. nidulans, Fusarium moniliforme, and F. solani; and two isolates of Scedosporium apiospermum) by the CLSI reference broth microdilution method (M38-A document). Control limits (amphotericin B, 1 to 4 μg/ml; itraconazole, 0.06 to 0.5 μg/ml; posaconazole, 0.03 to 0.25 μg/ml; voriconazole, 0.015 to 0.12 μg/ml) for the selected QC P. variotii ATCC MYA-3630 were established by the analysis of replicate MIC results. Reference isolates and corresponding MIC ranges were also established for 6 of the 12 molds evaluated. MIC limits were not proposed for the other five molds tested due to low testing reproducibility for these isolates.",
author = "A. Espinel-Ingroff and A. Fothergill and M. Ghannoum and E. Manavathu and L. Ostrosky-Zeichner and M. Pfaller and M. Rinaldi and W. Schell and T. Walsh",
year = "2005",
month = "10",
day = "1",
doi = "10.1128/JCM.43.10.5243-5246.2005",
language = "English (US)",
volume = "43",
pages = "5243--5246",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole

AU - Espinel-Ingroff, A.

AU - Fothergill, A.

AU - Ghannoum, M.

AU - Manavathu, E.

AU - Ostrosky-Zeichner, L.

AU - Pfaller, M.

AU - Rinaldi, M.

AU - Schell, W.

AU - Walsh, T.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Although standard conditions are available for testing the susceptibilities of filamentous fungi to antifungal agents by the Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) broth microdilution assay, quality control (QC) MIC limits have not been established for any mold-agent combination. This multicenter (eight-center) study documented the reproducibility of tests for one isolate of Paecilomyces variotti ATCC MYA-3630 and 11 other mold isolates (three isolates of Aspergillus fumigatus; two isolates of A. terreus; one isolate each of A. flavus, A. nidulans, Fusarium moniliforme, and F. solani; and two isolates of Scedosporium apiospermum) by the CLSI reference broth microdilution method (M38-A document). Control limits (amphotericin B, 1 to 4 μg/ml; itraconazole, 0.06 to 0.5 μg/ml; posaconazole, 0.03 to 0.25 μg/ml; voriconazole, 0.015 to 0.12 μg/ml) for the selected QC P. variotii ATCC MYA-3630 were established by the analysis of replicate MIC results. Reference isolates and corresponding MIC ranges were also established for 6 of the 12 molds evaluated. MIC limits were not proposed for the other five molds tested due to low testing reproducibility for these isolates.

AB - Although standard conditions are available for testing the susceptibilities of filamentous fungi to antifungal agents by the Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) broth microdilution assay, quality control (QC) MIC limits have not been established for any mold-agent combination. This multicenter (eight-center) study documented the reproducibility of tests for one isolate of Paecilomyces variotti ATCC MYA-3630 and 11 other mold isolates (three isolates of Aspergillus fumigatus; two isolates of A. terreus; one isolate each of A. flavus, A. nidulans, Fusarium moniliforme, and F. solani; and two isolates of Scedosporium apiospermum) by the CLSI reference broth microdilution method (M38-A document). Control limits (amphotericin B, 1 to 4 μg/ml; itraconazole, 0.06 to 0.5 μg/ml; posaconazole, 0.03 to 0.25 μg/ml; voriconazole, 0.015 to 0.12 μg/ml) for the selected QC P. variotii ATCC MYA-3630 were established by the analysis of replicate MIC results. Reference isolates and corresponding MIC ranges were also established for 6 of the 12 molds evaluated. MIC limits were not proposed for the other five molds tested due to low testing reproducibility for these isolates.

UR - http://www.scopus.com/inward/record.url?scp=26944500560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944500560&partnerID=8YFLogxK

U2 - 10.1128/JCM.43.10.5243-5246.2005

DO - 10.1128/JCM.43.10.5243-5246.2005

M3 - Article

C2 - 16207990

AN - SCOPUS:26944500560

VL - 43

SP - 5243

EP - 5246

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 10

ER -